Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia

NCT05878327 | Completed

• 1 other identifier: KEK-ZH-Nr. 2013-0301
• Study Type: observational
• Target: 15
• Locations: 1 country
• Sites: 3

Brief Summary

A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia.

Conditions

Livedoid Vasculitis

Keywords

Livedoid Vasculitis; smoking; thrombophilia

Outcome Measures

Primary Outcomes (1)

• Smoking history: Patients will be asked if they currently smoke or if they are former smokers. If one of both items is yes, it means a positive answer.

  The primary endpoint is the comparison of a positive smoking history and other cardiovascular risk factors of patients with livedoid vasculopathy with the Swiss general population.

  22 months

Secondary Outcomes (1)

• Thrombophilia screening: the following parameters will be determined in every participant: Factor V Leiden, Prothrombin 20210; Protein C, Protein S, Antithrombin III, Beta 2 Glykoprotein 1, Lupus Antikoagulans

  22 months

Study Arms (1)

Thrombophilia screening

Patients with livedoid vasculopathy. Investigated by thrombophilia screening

Other: Thrombophilia screening

Interventions

Thrombophilia screening OTHER

No intervention. Blood is drawn for analysis.

Thrombophilia screening

Eligibility Criteria

• Age: 10 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated for livedoid vasculopathy at the clinics of Dermatology of the University hospitals of Zurich, Basel and Bern.

You may qualify if:

• History of livedoid vasculopathy

You may not qualify if:

• Diagnosis was not proved by biopsy specimen
• A different reason than livedoid vasculopathy has been found for the symptoms of the patient
• No informed consent by the patient

Sponsors & Collaborators

• University of Zurich: lead

Study Sites (3)

University hospital of Basel

Basel, 4013, Switzerland

Location

University hospital of Bern

Bern, 3010, Switzerland

Location

University hospital Zurich

Zurich, 8091, Switzerland

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples for thrombophilia screen.

MeSH Terms

Conditions

Livedoid Vasculopathy; Smoking; Thrombophilia

Condition Hierarchy (Ancestors)

Thrombosis; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Skin Diseases, Vascular; Skin Diseases; Skin and Connective Tissue Diseases; Behavior; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Juerg Hafner, Prof, MD

  University Hospital Zurich, Dept. of Dermatology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 3, 2014
• First Posted: May 26, 2023
• Study Start: August 1, 2013
• Primary Completion: June 1, 2015
• Study Completion: June 1, 2015
• Last Updated: May 26, 2023

Record last verified: 2023-05

Locations

CH (3)